Tenderwize
Zurück zur Suche

Open-house rebate agreement for Aclidiniumbromid

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jan 03, 2028 · 493 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Aclidiniumbromid, ATC R03BB05

55/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

55 / 100

Komplexität

48 / 100

Risikofaktoren

Paper submissions must be sent in duplicate originals, and electronic submissions must use the DTVP communication area...

The notice limits participation to pharmaceutical companies and requires a signed declaration of reliability plus suppo...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2028
  • Non-exclusive pharmaceutical rebate agreement for the active substance Aclidiniumbromid (ATC R03BB05).
  • Open-house model with identical, non-individually negotiable contract terms for all eligible pharmaceutical companies.
Vollständige Zusammenfassung anzeigen

This is an open-house pharmaceutical rebate agreement for Aclidiniumbromid (ATC R03BB05) led by AOK Bayern. It is not a competitive award procedure: all interested pharmaceutical companies meeting the stated eligibility conditions may join on identical, non-negotiable terms. The contract period runs from 01.03.2026 to 29.02.2028, with contract entry possible until 03.01.2028. Submission is via DTVP or by signed paper originals; German language is required, and non-German documents must include a German translation.

Risiken

Paper submissions must be sent in duplicate originals, and electronic submissions must use the DTVP communication area...

The notice limits participation to pharmaceutical companies and requires a signed declaration of reliability plus suppo...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submit a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submit the completed and signed contract and the completed and signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreement for Aclidiniumbromid

Single lot open-house supply agreement for pharmaceutical rebate contracts concerning Aclidiniumbromid, ATC R03BB05. The lot is framework-like/open-house in nature, with no selection among bidders and identical contract terms for all eligible pharmaceutical companies. Performance is in Germany, Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Feb 2026 - Feb 2028

Kategorie

Pharmaceutical products

Frist

Deadline Jan 03, 2028

Vergabedetails

Veröffentlichungsdatum
13 Jan 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
25404-2026

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30